To understand the mechanisms underpinning genetic instability, the natural history and response to treatment of premalignant diseases, and the genetics of both blood and solid cancers. Mechanistic, genomic and evolutionary insights drive predictive biomarker development and the identification of new drug targets. This is made possible by significant investment in collections of clinically annotated cancer specimens and core bioinformatics support, which has provided an unrivalled opportunity to trace the genetic-clinical evolution of cancer over time. We not only seek to understand cancer genetics, but to apply this to patient outcomes, with the aim of improving diagnosis and stratifying personal treatment plans, to minimise treatment failure and maximise survival.
The main areas of focus are as follows: